Interestingly, when cells transfected with GSTO2 were treated with a p38 inhibitor, β-catenin expression and mitochondrial membrane potential were recovered, suggesting that GSTO-2 loss contributes to lung cancer progression, modulating tumour cells metabolism via the p38/β-catenin signalling pathway [347]. Here, GSTO2 is linked to lung carcinoma.